pp-274 Concentrate for solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Metastatic liver cancer
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Not disclosed
Route & form: IV infusion
Differentiation: it is a bispecific targets GPC3 and CD3,currently in Phase I/II clinical trials for the treatment of HCC(hepatocellular carcinoma).
Manufacturer #39685
A clinical-stage biopharmaceutical company focused on oncology. Developing a biologic therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None